Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258525 | 1.00 | KMT2A (0.48) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL258526 | 1.00 | KMT2A (0.48) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL6130221 | 0.87 | KMT2A (0.62) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL3787871 | 0.83 | KMT2A (0.52) | KMT2AMEN1MAPTCA12CA1 | |
| SCHEMBL3805335 | 0.82 | CA12 (0.44) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL3787003 | 0.81 | KMT2A (0.44) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL23658965 | 0.80 | KMT2A (0.60) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL4924251 | 0.80 | KMT2A (0.60) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL3791443 | 0.80 | KMT2A (0.60) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL31326080 | 0.80 | KMT2A (0.60) | KMT2AMEN1NPC1RAB9ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067642-B2 | Chiral phosphorous compounds | Celtice Catalysts Limited, Nova UCD (IE) | 2011-11-29 | — | — | US | disclosed |
| US-20100168456-A1 | CHIRAL PHOSPHOROUS COMPOUNDS | CELTIC CATALYSTS LIMITED (IE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168456-A1 | CHIRAL PHOSPHOROUS COMPOUNDS | RPP30, PLCB3, INPP5D | KMT2A 4432/4885MEN1 544/4885MAPT 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.